No Data
Incyte Zynyz Improves Progression-free Survival in Anal Cancer
Unusual Options Activity: F, INCY and Others Attract Market Bets, F V/OI Ratio Reaches 416.7
EST Sep 12th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
BofA Securities Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $66
BofA Securities analyst Tazeen Ahmad maintains $Incyte(INCY.US)$ with a hold rating, and adjusts the target price from $62 to $66.According to TipRanks data, the analyst has a success rate of 50.7%
Incyte's CDK2i: A Cautiously Optimistic Neutral Rating Amidst Early Clinical Data and Safety Concerns
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cantor Fitzgerald Reiterates Neutral on Incyte